DALLAS, Aug. 8, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces a stock report featuring Dendreon Corp. (Nasdaq:DNDN). The report briefly notes the company's most recent developments and news, and outlines its financial position, market performance, and comparison against industry peers.
The full report is available at: www.microstockprofit.com/lp/DNDN
Dendreon Corp. (DNDN) is a biotechnology company engaged in the discovery, development, and commercialization of therapeutics to enhance cancer treatment options for patients. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. DNDN's first product, Provenge (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. The Company is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers.
This newsletter has been helping traders make great investment decisions on DNDN; click here for a 25% discount offer.
In the report, the analyst notes:
"DNDN shares traded as much as 10.8% higher Friday, reversing the previous session's huge drop on a report the cancer drug maker is pulling its sales forecast for its prostate cancer vaccine, Provenge, following lower-than-expected sales."
"For the second quarter ended June 30, 2011, the Company posted a GAAP net loss of $114.6 million, or $0.79 per share, compared to a net loss of $142.6 million, or $1.04 per share for the quarter ended June 30, 2010."
To read the entire report visit: www.microstockprofit.com/lp/DNDN
See what investors are saying about DNDN at http://www.stockhideout.com
Get breaking news on DNDN at http://thestockmarketwatch.com/
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.